Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Expenses (2021 - 2023)

Historic Operating Expenses for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to $45.5 million.

  • Cullinan Therapeutics' Operating Expenses rose 3949.03% to $45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $190.6 million, marking a year-over-year increase of 4428.13%. This contributed to the annual value of $196.9 million for FY2024, which is 328.88% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Operating Expenses stood at $45.5 million for Q4 2023, which was up 3949.03% from $44.8 million recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' Operating Expenses registered a high of $62.8 million during Q1 2023, and its lowest value of $16.6 million during Q2 2021.
  • Its 3-year average for Operating Expenses is $34.1 million, with a median of $33.5 million in 2021.
  • The largest annual percentage gain for Cullinan Therapeutics' Operating Expenses in the last 5 years was 12347.63% (2022), contrasted with its biggest fall of 506.3% (2022).
  • Cullinan Therapeutics' Operating Expenses (Quarter) stood at $34.3 million in 2021, then decreased by 5.06% to $32.6 million in 2022, then skyrocketed by 39.49% to $45.5 million in 2023.
  • Its Operating Expenses stands at $45.5 million for Q4 2023, versus $44.8 million for Q3 2023 and $37.6 million for Q2 2023.